COMMUNIQUÉS West-GlobeNewswire

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

14/01/2025 - 14:00

First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025 Phase 2 trial of VTX2735 in participants with recurrent [...]

Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection

14/01/2025 - 14:00

MALVERN, Pa, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases [...]

E8, Inc. Announces Collaborative Partnership with Jacobs Institute to Make Minimally Invasive Solutions the Gold Standard in Neurosurgery

14/01/2025 - 14:00

Minimally Invasive Surgical Access Systems Require Dedicated Instruments to Transform Neurosurgery LOS GATOS, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- E8, Inc. unveiled its next-generation suite of tools designed to [...]

Bionano Announces Use of OGM in Preimplantation Genetic Testing as Part of Successful Live Birth to a Couple Experiencing Recurrent Pregnancy Loss

14/01/2025 - 14:00

OGM uniquely identified a complex chromosomal rearrangement missed by classical cytogenetics, helping clinical researchers apply targeted screening to select the most fit embryos for transfer Following in-vitro [...]

Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody® ADG126 in Advanced/Metastatic Microsatellite-Stable (MSS) Colorectal Cancer (CRC) on January 25, 2025

14/01/2025 - 14:00

SAN DIEGO and SUZHOU, China, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced it will [...]

Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs

14/01/2025 - 14:00

COVID-19 Phase 2b study poised to initiate 10,000 participant portion of trial pending U.S. Food and Drug Administration (FDA) review of sentinel cohort 30-day safety data Norovirus program to proceed with Phase 1 study [...]

Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference

13/01/2025 - 22:35

MELBOURNE, Australia and INDIANAPOLIS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today advises that Dr. Christian Behrenbruch, Managing Director and [...]

GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial

13/01/2025 - 22:10

Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 13 janvier 2025 – GENFIT (Nasdaq et Euronext: GNFT) , société biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie [...]

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

13/01/2025 - 22:10

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 13, 2025 – GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients [...]

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

13/01/2025 - 22:05

AMF Regulated Information Châtillon, France, January 13, 2025 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), [...]

Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF

13/01/2025 - 22:05

Informations Réglementées Châtillon, France, le 13 janvier 2025 Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq : DBVT), [...]

OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2024 and Issues 2025 Financial Guidance

13/01/2025 - 22:00

Achieves all-time high full year 2024 Revenue of $205 million representing growth of 38% Year-Over-Year Initiates guidance for record adjusted EBITDA in 2025 WARSAW, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- [...]

Micron Biomedical Wins $2 Million BARDA Competition for Its Collaboration with Zipcode Bio to Develop mRNA-Based Broad Protecting Flu Vaccine Without Needles

13/01/2025 - 20:00

U.S. Department of Health and Human Services (HHS) office, BARDA, awards Micron $2 million to continue its work on broadly-protecting avian and seasonal flu vaccines SAN FRANCISCO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- [...]

Merus et Biohaven annoncent une collaboration pour co-développer trois nouveaux programmes de CAM bispécifiques

13/01/2025 - 18:24

NEW HAVEN, Connecticut, et UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 13 janv. 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE : BHVN) et Merus N.V. (Nasdaq : MRUS) ont annoncé ce jour une collaboration de recherche et [...]

Correction: GUERBET : Financial agenda for 2025

13/01/2025 - 18:00

Financial agenda for 2025 Villepinte, 13 janvier 2025 : Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2025. Publications [...]

Correction: GUERBET : Calendrier financier de l'exercice 2025

13/01/2025 - 18:00

Calendrier financier de l’exercice 2025 Villepinte, le 13 janvier 2025 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, publie son calendrier financier [...]

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer

13/01/2025 - 18:00

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer NANTES, France, January 13, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , today announced the [...]

OSE Immunotherapeutics annonce la nomination du Dr. Sonya Montgomery au poste de Chief Development Officer

13/01/2025 - 18:00

OSE Immunotherapeutics annonce la nomination du Dr. Sonya Montgomery au poste de Chief Development Officer Nantes, France, le 13 janvier 2025, 18 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) [...]

Press release: Transparency Notification from Shareholders

13/01/2025 - 17:30

Transparency Notification from Shareholders Ghent, Belgium – 13 January 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a pioneer in the treatment of fluid overload in [...]